Siren, L.L.C. Arcus Biosciences, Inc. Transaction History
Siren, L.L.C.
- $2 Trillion
- Q3 2024
A detailed history of Siren, L.L.C. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Siren, L.L.C. holds 1,612,077 shares of RCUS stock, worth $26.5 Million. This represents 1.23% of its overall portfolio holdings.
Number of Shares
1,612,077Holding current value
$26.5 Million% of portfolio
1.23%Shares
1 transactions
Others Institutions Holding RCUS
# of Institutions
202Shares Held
50.5MCall Options Held
173KPut Options Held
151K-
Black Rock Inc. New York, NY9.76MShares$160 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.47MShares$89.9 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA4.25MShares$69.7 Million0.65% of portfolio
-
State Street Corp Boston, MA3.01MShares$49.5 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.83MShares$30.1 Million0.08% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.19B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...